These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26308250)

  • 1. Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials.
    Aprile G; Fontanella C; Bonotto M; Rihawi K; Lutrino SE; Ferrari L; Casagrande M; Ongaro E; Berretta M; Avallone A; Rosati G; Giuliani F; Fasola G
    Oncotarget; 2015 Oct; 6(30):28716-30. PubMed ID: 26308250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
    Methy N; Bedenne L; Bonnetain F
    BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surrogate endpoints for overall survival in lung cancer trials: a review.
    Fiteni F; Westeel V; Bonnetain F
    Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
    Ciani O; Buyse M; Garside R; Peters J; Saad ED; Stein K; Taylor RS
    J Clin Epidemiol; 2015 Jul; 68(7):833-42. PubMed ID: 25863582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endpoints in cancer clinical trials.
    Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
    J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individual- and trial-level surrogacy in colorectal cancer.
    Buyse M; Burzykowski T; Michiels S; Carroll K
    Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.
    Sidhu R; Rong A; Dahlberg S
    Clin Cancer Res; 2013 Mar; 19(5):969-76. PubMed ID: 23303214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.
    Ciani O; Davis S; Tappenden P; Garside R; Stein K; Cantrell A; Saad ED; Buyse M; Taylor RS
    Int J Technol Assess Health Care; 2014 Jul; 30(3):312-24. PubMed ID: 25308694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
    Tate Thigpen J
    Gynecol Oncol; 2015 Jan; 136(1):121-9. PubMed ID: 25455732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments.
    Piedbois P; Buyse M
    Curr Opin Oncol; 2008 Jul; 20(4):466-71. PubMed ID: 18525345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
    Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
    Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective.
    Piedbois P; Miller Croswell J
    Stat Methods Med Res; 2008 Oct; 17(5):519-27. PubMed ID: 18285441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
    Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-Pélissier S; Bonnetain F
    Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
    Wilson MK; Karakasis K; Oza AM
    Lancet Oncol; 2015 Jan; 16(1):e32-42. PubMed ID: 25638553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer.
    Elia EG; Städler N; Ciani O; Taylor RS; Bujkiewicz S
    Cancer Epidemiol; 2020 Feb; 64():101665. PubMed ID: 31911395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.
    Giessen C; Laubender RP; Ankerst DP; Stintzing S; Modest DP; Mansmann U; Heinemann V
    Clin Cancer Res; 2013 Jan; 19(1):225-35. PubMed ID: 23149819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma.
    Louvet C; de Gramont A; Tournigand C; Artru P; Maindrault-Goebel F; Krulik M
    Cancer; 2001 Jun; 91(11):2033-8. PubMed ID: 11391582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermediate markers as surrogate endpoints in cancer research.
    Schatzkin A
    Hematol Oncol Clin North Am; 2000 Aug; 14(4):887-905. PubMed ID: 10949779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.